Optical Preclinical Imaging Market Growth Analysis | 2022-2028

Market Insights

The Optical Preclinical Imaging Market was estimated at US$ 619 million in 2021 and is expected to grow at a CAGR of 4.8% during 2022-2028 to reach US$ ~861.1 million in 2028.

Wish to get a free sample? Register Here

What is optical preclinical imaging?

Optical preclinical imaging is a non-invasive, high-resolution imaging technique used in biomedical research to visualize and study small animals, such as mice and rats, for preclinical drug development and disease modeling. It employs various optical modalities, including bioluminescence and fluorescence imaging, to capture real-time, in vivo data on biological processes and disease progression

Market Dynamics

Biomedical research has taken center stage in the healthcare and pharmaceutical industries, to the point where a country's R&D landscape can be gauged by its amount of expenditure on biomedical research. As a result, most wealthy and developing countries have seen a startling increase in biomedical research over the last decade. Animal models typically receive a sizable portion of this research funding. This is a major driving force in the worldwide optical preclinical imaging market.

The increased use of optical preclinical imaging is also related to the recent number of advancements in optical preclinical imaging technologies. These enhancements have not only expanded its utility in existing applications but have also broadened the total field of preclinical imaging.

Increased demand for non-invasive imaging techniques, as well as government support for research and development, are projected to drive the global preclinical imaging market. However, the worldwide preclinical imaging market is expected to be restricted by factors such as high product prices, which reduce adoption rates at academic institutions, and a limited number of applications for each modality, which discourages product sales.

Despite tremendous political and economic uncertainties in recent years, the healthcare business remains vibrant in terms of expenditures directed to R&D and the introduction of novel and technologically sophisticated medical devices, medical imaging equipment, and pharmaceutical and biopharmaceutical goods. This has forced the creation of preclinical imaging and new types of in vivo preclinical imaging for testing new ways for clarifying disease progression, disease genesis, and metastasis & progression of malignancies.

The rise in the usage of optical preclinical imaging is primarily owing to advances in molecular imaging technology. Nuclear medicine and molecular imaging have advanced significantly and continue to evolve, enhancing their impact on diagnosis and therapy. The rising frequency of chronic diseases, an ageing population, and more limited global resources are among the primary factors driving the evolution of the nuclear medicine and molecular imaging industries. Advanced imaging and hybrid modalities like computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET)/CT, and single-photon emission computed tomography (SPECT)/CT are gaining popularity. Furthermore, molecular imaging has enabled tailored therapy based on individual needs. In addition, there has been a significant increase in demand for noninvasive small animal imaging techniques.

The increase in overall population has resulted in an increase in chronic diseases as well as the appearance of new diseases. Furthermore, this has resulted in the discovery and development of novel therapeutic compounds. Preclinical research is undertaken on animals through clinical trials to examine the safety and efficacy of these potential medication candidates before testing them on people. Furthermore, increased financing for preclinical research by both commercial and public entities drives market expansion. The high cost of optical preclinical imaging, on the other hand, is a major deterrent factor in the global market. Furthermore, optical preclinical imaging systems necessitate frequent maintenance, which incurs additional costs, stifling worldwide market growth.

Several investments/guidelines in the industry have been directed in recent years, which would boost the overall market:

• In live animal research for drug development, optical preclinical imaging is used. Optical preclinical imaging is also utilized to monitor treatment response for early efficacy indications. Technological advancements in in vivo imaging allow for quantitative research of disease at the molecular level. In vivo imaging serves as a link between in vitro exploratory and in vivo clinical research, allowing for the direct and rapid translation of preclinical investigations on animal models to clinical trials in humans. Cancer, autoimmune illnesses, neurological disorders, and cardiovascular diseases are the primary disease areas targeted by in vivo preclinical imaging.

Segments Analysis

By Product Type

The market has been segmented into bioluminescence & fluorescence imaging systems, standalone fluorescence imaging systems, and optical + x-ray & optical + CT.

By Application Type

The optical preclinical imaging market has been divided into drug discovery and others.

Regional Analysis

The optical preclinical imaging market is broken down geographically into areas like North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Because of its well-established pharmaceutical and biopharmaceutical research sector, North America dominated the global optical preclinical imaging market in 2021, and this trend is expected to continue over the projected period. The region's presence of the world's largest pharmaceutical and biopharmaceutical companies makes it a very attractive market for various items used in research operations. Because of its well-established medication manufacturing sector and the existence of the world's most important research laboratories and research-oriented universities, Europe held a considerable share of the worldwide optical preclinical imaging market in 2021.

Key Players

The following are the major players in the optical preclinical imaging market:

• Bruker Corporation
• FUJIFILM Holdings America Corporation
• Mediso Ltd.
• MILabs B.V
• Miltenyi Biotec
• MR Solutions
• PerkinElmer, Inc.
• TriFoil Imaging
• UVP
• Vieworks Co., Ltd.

The global optical preclinical imaging market is fragmented, with both small and large-scale companies present. For example:

• Vieworks presented its optical in vivo imaging devices at the AACR Annual Meeting in April 2022. Vieworks' premier preclinical optical imaging system for high-sensitivity fluorescence and bioluminescent imaging is VISQUE InVivo Art (350 - 950 nm). It has a 10-mice/5-rats FOV and ultra-low noise, and the camera temperature can be as low as -100°C. Users can enjoy high-quality images with a resolution of 2048 x 2048 pixels (ART 400); and 1024 x 1024 pixels (ART 400). (ART 100). Researchers can tailor fluorescent filters (emission filters: 350-950 nm, excitation filters: 440-700 nm) to their own needs. The VISQUE InVivo Smart-LF has a small footprint and is ideal for small and individual laboratories. It features a scientific CMOS camera with cooling technology, high-sensitivity imaging from 300 to 940 nm, and quick picture acquisition (max. 37 fps). CleVue, Vieworks' in vivo image acquisition and analysis software specific to the VISQUE InVivo series, is included with both systems. It has highly potent analysis capabilities such as ROI, quantification, kinetic analysis, and easy-to-use reporting. The software has been developed over several years in close collaboration with researchers to give the simplest and most straightforward analysis to boost small animal studies.
• In September 2020, AXT expanded its preclinical imaging product portfolio with the Vieworks line of bio-imaging devices. Their in-vivo imaging systems perform admirably in bioluminescent and fluorescence imaging and offer excellent value. The VISQUE bio-imaging range will be useful to medical researchers working in Translational Research areas such as drug discovery, cancer research, and many more.

Research Methodology

This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data. We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

Report Features

This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

What Deliverables Will You Get in this Report?

Customization Options

With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

Company Profiling

• Detailed profiling of additional market players (up to three players)
• SWOT analysis of key players (up to three players)

Competitive Benchmarking

• Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances

Custom Research: Stratview Research offers custom research services across the sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com